Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Biomarcador para la predicción y monitorización eficiente del factor alfa de necrosis tumoral en terapias de inhibición inflamatoria

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20190215001
Publicado:
29/04/2019
Caducidad:
29/04/2020
Resumen:
Un instituto de investigación alemán ha generado datos positivos sobre el uso de la proteína interleucina 22 como biomarcador para la predicción y monitorización de la eficacia individual de tratamientos anti-TNT-alfa de la enfermedad intestinal inflamatoria y otras patologías inflamatorias crónicas. La monitorización de IL-22BP puede emplearse para predecir la eficacia de la terapia y para medir la evolución de la enfermedad en pacientes tratados. El instituto busca pymes y multinacionales especializadas en el desarrollo de estos tratamientos, especialmente para la optimización de la terapia anti-TNT-alfa. La cooperación se establecerá en el marco de un acuerdo de licencia, transferencia de derechos o I+D.

Details

Tittle:
Biomarker for efficient prediction and monitoring of tumor necrosis factor alpha in inflammation inhibition therapies
Summary:
A German research institution has generated positive data on the use of interleukin-22 binding protein as biomarker for prediction and monitoring of the individual efficacy of anti-TNF-alpha treatments of Inflammatory Bowel Disease and other chronic inflammatory conditions. Sought are SMEs and MNEs of any size, which are involved in the development of such treatments, especially for optimization of anti-TNF-alpha therapy for licensing, transfer of rights, knowledge transfer, or R-Y-D cooperation.
Description:
The pathogenesis of Inflammatory Bowel Disease (IBD) remains still unclear, yet it has been closely related to the inflammatory response. Current therapies target tumor necrosis factor alpha (TNF-alpha) to inhibit its inflammatory effects. The success of the therapy is monitored through observation of clinical symptoms and TNF-alpha antibodies level. This yields a limited amount of information, since the effects of the treatment are only detectable with the development of the patient´s wellbeing, hence in only ~ 50 % of the cases TNF-alpha-based treatments of IBD have the expected therapeutic effect. This inefficient monitoring entails remarkable disadvantages for the patient and health system, due to the side effects and high costs associated to TNF-alpha-blockers treatment.

A German research group has generated positive data on the novel use of interleukin-22 binding protein (IL-22BP) as biomarker for the prediction and monitoring of the efficacy of anti-TNF-alpha treatments, allowing its consistent use. IL-22BP regulates the function of the free interleukin, and its downregulation apparently has a positive effect on the therapy. Therefore, monitoring IL-22BP could be used to predict therapy effectiveness and for measuring the course of the disease in treated patients. This would allow an early adaption or optimization of therapy conditions to the patient in a usually lifelong treatment thereby reducing costs and increasing wellbeing. The positive results generated so far are being currently validated in the frame of a prospective study.

Partners could be enterprises of any size, both SMEs or MNEs, which are preferably active in the fields of Inflammatory Bowel Disease treatment, optimization of anti-TNF-alpha therapy, and personalized medicine. They could benefit from a transfer of rights of the existing IP (patent pending), licensing, knowledge transfer, or R-Y-D collaborations to test and refine the technology in commercially relevant projects. In focus of a possible collaboration could be the development of a market-ready diagnostic assay, or the support of prospective studies with larger groups of patients.
Advantages and Innovations:
Reduced treatment time
Reduced treatment costs
Minimization of related side effects
Personalization to patient
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
PCT application pending

Partner sought

Type and Role of Partner Sought:
Sought are industrial partners of any size, both SMEs or MNEs, which are preferably involved in the treatment of Inflammatory Bowel Disease, optimization of anti-TNF-alpha therapy, and personalized medicine in general.

Partners are sought for licensing, transfer of rights (pending patent), knowledge transfer, or R-Y-D collaborations to test and refine the technology in commercially relevant projects. In focus of a possible collaboration could be the development of a market-ready diagnostic assay, or the support of prospective studies with larger groups of patients.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
German

Keywords

Technology Keywords:
01004001 Applications for Health
06001005 Diagnósticos, diagnosis
06001002 Investigaciones clínicas, ensayos
03004007 Pharmaceutics